Nuvectis Pharma Inc
NVCT
NASDAQ
Biotechnology
$18.96
USD
-0.27 (-1.40%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $626.54M
Volume 106.7K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-27.85M
TTM
-26.2%
YoY
Operating Cash Flow
$-19.51M
TTM
-57.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.0 | 2.0 | 2.5 | 2.2 | 2.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 6.6 | 7.8 | 7.6 | 6.3 | 7.2 |
Operating Income | -6.6 | -7.8 | -7.6 | -6.3 | -7.2 |
EBITDA | -6.6 | -7.8 | -7.6 | -6.3 | -7.2 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 |
Income Before Income Taxes | -6.3 | -7.5 | -7.3 | -6.1 | -7.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -6.3 | -7.5 | -7.3 | -6.1 | -7.0 |
Consolidated Net Income / Loss | -6.3 | -7.5 | -7.3 | -6.1 | -7.0 |
Net Income Attributable to Common Shareholders | -6.3 | -9.9 | -7.3 | -6.1 | -7.0 |
Basic EPS | -$0.30 | -$0.44 | -$0.31 | -$0.26 | -$0.30 |
Diluted EPS | -$0.30 | -$0.44 | -$0.31 | -$0.26 | -$0.30 |
Basic Shares Outstanding | 21.4M | 22.7M | 23.2M | 23.4M | 23.5M |
Diluted Shares Outstanding | 21.4M | 22.7M | 23.2M | 23.4M | 23.5M |